Skip to main content
Sansure Biotech Inc. logo

Sansure Biotech Inc. — Investor Relations & Filings

Ticker · 688289 ISIN · CNE1000043J1 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 871 across all filing types
Latest filing 2023-10-30 Board/Management Inform…
Country CN China
Listing Shanghai Stock Exchange 688289

About Sansure Biotech Inc.

https://www.sansureglobal.com/

Sansure Biotech Inc. specializes in the development and manufacture of molecular diagnostic products and genetic testing solutions. The company utilizes proprietary technologies, such as the "One-tube" fast extraction method and advanced magnetic bead technology, to provide high-sensitivity PCR diagnostic kits. Its product portfolio covers a wide range of clinical applications, including infectious disease screening for hepatitis, respiratory infections, and sexually transmitted infections, as well as oncology and maternal health. Sansure also provides integrated laboratory automation systems, including nucleic acid extractors and real-time PCR instruments, designed to streamline clinical workflows and improve diagnostic efficiency for healthcare providers and research institutions globally.

Recent filings

Filing Released Lang Actions
圣湘生物科技股份有限公司独立董事关于第二届董事会2023年第十一次临时会议相关事宜的独立意见
Board/Management Information Classification · 90% confidence The document is an independent opinion from the independent directors of 圣湘生物科技股份有限公司 regarding several proposals to be submitted to the shareholders' meeting, including related party investment, profit distribution for the first three quarters of 2023, and a three-year dividend plan. It references compliance with laws and regulations and the submission of these matters to the shareholders' meeting for approval. The document is not a full report but an opinion related to board matters and shareholder meeting agenda items. It does not contain financial statements or detailed financial data, nor is it a voting result announcement. This fits best under Board/Management Information (MANG) as it concerns board opinions on corporate governance matters and proposals for shareholder consideration.
2023-10-30 Chinese
圣湘生物科技股份有限公司第二届监事会2023年第九次临时会议决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board of 圣湘生物科技股份有限公司 regarding several agenda items including approval of the 2023 Q3 report, investment decisions, profit distribution plans, and a three-year dividend plan. It contains voting results and states that some matters will be submitted to the shareholders' meeting. The document is relatively short (1971 characters) and primarily announces decisions and approvals rather than containing the full financial report or detailed financial data. It also references that the full 2023 Q3 report and other announcements are published separately on the Shanghai Stock Exchange website. Therefore, this document is an official announcement of meeting resolutions and approvals, not the full interim/quarterly report itself. This fits best with the category of Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories.
2023-10-30 Chinese
圣湘生物科技股份有限公司关于召开2023年第四次临时股东大会的通知
AGM Information Classification · 95% confidence The document is a notice about convening the 2023 fourth extraordinary general meeting of shareholders for 圣湘生物科技股份有限公司. It details the meeting date, voting methods, agenda items, and procedural instructions for shareholders. It does not contain financial statements or results but is an announcement of a shareholder meeting. The document length is about 3000 characters, which is relatively short and consistent with a meeting notice rather than a full report. Therefore, it fits the category of AGM Information (AGM-R), which covers presentations and materials shared during the Annual General Meeting or similar shareholder meetings.
2023-10-30 Chinese
圣湘生物科技股份有限公司2023年第三季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled '2023 年第三季度报告' which translates to '2023 Third Quarter Report'. It contains detailed financial data including consolidated balance sheets, profit and loss statements, cash flow statements, and notes on accounting policies. The report covers the third quarter period of 2023 and includes unaudited financial statements. The presence of comprehensive financial statements and analysis for a period shorter than a full fiscal year indicates this is an Interim / Quarterly Report. There is no indication that this is an announcement or a certification document, and the length and detail confirm it is the report itself, not just a publication announcement. Therefore, the appropriate classification is Interim / Quarterly Report (IR). 9M 2023
2023-10-30 Chinese
圣湘生物科技股份有限公司独立董事关于第二届董事会2023年第十一次临时会议相关事宜的事前认可意见
Board/Management Information Classification · 95% confidence The document is a statement from independent directors of a company regarding their prior approval opinion on a specific board meeting matter related to investment and waiver of preemptive rights. It references compliance with listing rules and independent director management measures. The content is about board-level approval and opinions rather than financial results, audit, or shareholder voting results. It is not a full report, earnings release, or regulatory filing but rather a management/board-related announcement. Therefore, it fits best under Board/Management Information (MANG). The document is short and focused on board matters, not a report or announcement of a report publication.
2023-10-30 Chinese
圣湘生物科技股份有限公司关于2023年前三季度利润分配方案的公告
Notice of Dividend Amount Classification · 95% confidence The document is a formal announcement from 圣湘生物科技股份有限公司 regarding the profit distribution plan for the first three quarters of 2023. It details the dividend per share, the total amount to be distributed, and the conditions for the distribution. It also mentions that the plan needs to be submitted to the shareholders' meeting for approval. The document is relatively short (1460 characters) and focuses on the dividend distribution scheme rather than presenting full financial statements or detailed financial analysis. This fits the definition of a Notice of Dividend Amount (DIV), which announces dividend amounts, payment dates, and related details for shareholders.
2023-10-30 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.